Payment overview · 2025
General Payments
$1,739.68
54 reported records · 18 companies
Healthcare provider profile · identity verified
David G Holmes, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · OPELIKA, AL · NPI 1467489286
Verified facts
What the public records show
CMS Open Payments records show David G Holmes, MD received $1,739.68 in general payments during 2025 across 54 reported records.
Medtronic, Inc. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Adempas, Opsumit.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Opsumit by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 3385 records involving 1868 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Adempas by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 610 claims for Eliquis by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 14 records involving 2 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Adempas by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 610 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$392.84 | 22.6% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $202.78 | 11.7% | 6 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $194.86 | 11.2% | 3 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $133.67 | 7.7% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $120.37 | 6.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $104.44 | 6.0% | 6 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $100.00 | 5.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $89.06 | 5.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.93 | 5.0% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $70.26 | 4.0% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $61.32 | 3.5% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $58.25 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.81 | 2.2% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $21.25 | 1.2% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $19.40 | 1.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.22 | 1.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.55 | 0.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.67 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,739.68 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $194.86 | 3 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $161.32 | 2 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $153.07 | 3 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $133.67 | 5 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $120.37 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $104.44 | 6 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $87.93 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $87.93 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $87.18 | 5 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $70.26 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.76 | 3 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $58.25 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $40.91 | 2 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $40.63 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $37.81 | 2 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $32.56 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| Adempas Normalized: adempas |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
| AMPLIA MRI QUAD CRT-D SURESCAN Normalized: amplia mri quad crt d surescan |
Device | Medtronic, Inc. | $5.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Adempas adempas |
2025 | Adempas | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
85 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 3385 supporting records · 1868 recipient NPIs · example record 1225434673 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
610 | 146 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 14 supporting records · 2 recipient NPIs · example record 1237996458 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
610 | 146 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 610 | 146 |
| Atorvastatin Calcium | Atorvastatin Calcium | 606 | 216 |
| Losartan Potassium | Losartan Potassium | 402 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 132 |
| Carvedilol | Carvedilol | 325 | 112 |
| Metoprolol Succinate | Metoprolol Succinate | 288 | 110 |
| Furosemide | Furosemide | 266 | 119 |
| Amiodarone Hcl | Amiodarone Hcl | 251 | 97 |
| Clopidogrel | Clopidogrel Bisulfate | 245 | 86 |
| Repatha Sureclick | Evolocumab | 232 | 44 |
| Entresto | Sacubitril/Valsartan | 213 | 38 |
| Sotalol | Sotalol Hcl | 190 | 67 |
| Xarelto | Rivaroxaban | 165 | 41 |
| Lisinopril | Lisinopril | 157 | 63 |
| Valsartan | Valsartan | 133 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 46 |
| Ranolazine Er | Ranolazine | 121 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 43 |
| Spironolactone | Spironolactone | 95 | 43 |
| Atenolol | Atenolol | 88 | 26 |
| Warfarin Sodium | Warfarin Sodium | 88 | 21 |
| Brilinta | Ticagrelor | 85 | 21 |
| Farxiga | Dapagliflozin Propanediol | 71 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 25 |
| Potassium Chloride | Potassium Chloride | 65 | 22 |
| Adempas | Riociguat | 61 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 16 |
| Ezetimibe | Ezetimibe | 60 | 21 |
| Bumetanide | Bumetanide | 50 | 17 |
| Opsumit | Macitentan | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 14 |
| Simvastatin | Simvastatin | 45 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 18 |
| Praluent Pen | Alirocumab | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 26 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Multaq | Dronedarone Hcl | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Omeprazole | Omeprazole | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Gabapentin | Gabapentin | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 16 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,739.68 · 54 records | Medtronic, Inc. | AMPLIA MRI QUAD CRT-D SURESCAN, Adempas, Ambulatory Monitoring & Diagnostics Undivided, CAMZYOS, CAPVAXIVE, General - Brady, INSPIRE, Kerendia, LINQ II, LifeVest, MICRA, NEXLETOL, ONYX FRONTIER, OPSUMIT, OPSYNVI, Ozempic, Paradise Ultrasound Renal Denervation System, REPATHA, Rybelsus, SYMPLICITY G3, Serrantor, Tyvaso, UPTRAVI, VERQUVO, VYNDAQEL, WAINUA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Adempas play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error